Citius Oncology Inc expected to post a loss of 1 cent a share - Earnings Preview

Citius Pharmaceuticals Inc
Tenx Keane Acquisition

Citius Pharmaceuticals Inc

CTXR

0.00

Tenx Keane Acquisition

CTOR

0.00

  • Citius Oncology Inc CTOR.OQ CTOR.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2026

  • The Cranford New Jersey-based company is expected to report revenue of $6.997 million, according to the estimate from one analyst, based on LSEG data.

  • ​LSEG's mean analyst estimate for Citius Oncology Inc is for a loss of 1 cent per share.

  • The one available analyst rating on the shares is "buy".

  • The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​

  • Wall Street's median 12-month price target for Citius Oncology Inc is $6.00, about 566% above its last closing price of $0.90

This summary was machine generated May 8 at 21:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.